The Antibody Society announces the election of new Directors and Officers
The Antibody Society, Inc., an international non-profit trade association focused on the advancement of antibody research and development, is pleased to announce the election of Drs. Katherine Harris...
View ArticleThe Antibody Society is hiring!
Come join The Antibody Society in our mission to help people involved or interested in antibody research and development. We seek a Marketing and Events Manager to provide expertise in promoting our...
View ArticleWorld Cancer Day 2024 – Antibody therapeutics for cancer indications
For World Cancer Day 2024, The Antibody Society has prepared a snapshot of the clinical development of therapeutic antibodies for cancer indication. The infographic gives an overview on the trends in...
View ArticleCrovalimab approved in China
On February 8, 2024, Chugai Pharmaceutical Co., Ltd. announced that crovalimab (Chinese product name : 派圣凯®) was approved in the People’s Republic of China for treatment of adults and adolescents with...
View ArticleCall for papers – Innovative approaches to antibody therapeutics discovery:...
The Antibody Society’s latest analysis of the current early-stage clinical pipeline of antibody therapeutics shows that the biopharmaceutical industry is engaging in innovative research and...
View ArticleLearn how to harness the power of ADCs in our next webinar!
Join us for our next webinar! Antibody-drug conjugates (ADCs) have emerged as an important class of targeted therapeutics, combining the targeting specificity of antibodies with the potency of...
View ArticleTEVIMBRA (tislelizumab-jsgr) granted first FDA approval for esophageal...
On March 13, 2024, the U.S. Food and Drug Administration (FDA) approved TEVIMBRA (tislelizumab-jsgr) as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal...
View ArticleVisit us at Antibody Engineering & Therapeutics, Booth #113!
Antibody Engineering & Therapeutics commences on Thursday, December 14, 2023! Visit us at Booth #113 for a free T shirt and networking. And don’t miss the keynote address by Dr. Heather Bax, the...
View Article“Antibodies to Watch in 2024” is now online!
In this 15th installment of the annual ‘Antibodies to Watch’ article series, we review commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical development, regulatory...
View ArticleJoin us on April 25 to learn how to harness divergent species to access...
Registration is open! To exploit highly conserved and difficult drug targets, including GPCRs and ion channels, monoclonal antibody discovery efforts are increasingly relying on the advantages offered...
View Article
